ABSTRACT Terbutaline, a cardioselective beta-adrenoceptor agonist, administered intravenously (250 jg) to seven patients with chronic obstructive airways disease (mean 
The precise mechanism by which chronic increase in airways resistance leads to pulmonary hypertension in some patients is still controversial. At present the evidence favours a multifactorial aetiology in which chronic hypoxaemia probably has a dominant role to play.1 2 Peak expiratory flow rate was measured in triplicate at rest only, by a mini Wright's peak flow nmeter. The coefficient of variation of the PEFR with this instrument was calculated from triplicate readings taken from 10 volunteers and was found to be 1%.
MEASUREMENTS, CALCULATIONS, AND STATISTICAL ANALYSIS
Phasic pressure measurements were averaged over two complete respiratory cycles. Mean pressures were measured by electronic integration. Systemic and pulmonary vascular resistances were calculated according to known formulae.7 Venous admixture was estimated from the shunt equation using the calculated ideal alveolar oxygen tension.8 Heart rate was measured from five electrocardiographic complexes. The probability of significance of changes between paired samples was determined by Student's t test.
Results
The injection of terbutaline in the pulmonary artery did not cause any untoward symptoms.
The heart rate, intravascular pressures, and electrocardiogram did not show any immediate changes.
EFFECT ON HEART RATE, OXYGEN UPTAKE, CARDIAC OUTPUT, AND STROKE VOLUME (FIG 1) As compared to the control study a significant increase in heart rate was observed both at rest (p<0-01) and on exercise (p<0-01). Cardiac output was normal in all the patients at rest and 13 Finally, disease of the left ventricle may be responsible for an increase in wedge pressure even if meticulous care has been taken to exclude common causes on clinical grounds.
The mechanism by which terbutaline reduced pulmonary artery pressure is purely speculative. A significant reduction in the arteriovenous pressure difference in face of a considerable rise in flow suggests an appreciable increase in the pulmonary vascular capacitance. Although we did not measure central blood volume in the present study, collateral evidence from studies with the beta-receptor agonist isoprenaline in patients with COAD indicate that the reduction in pulmonary vascular resistance is accompanied by an increase in the pulmonary blood volume. '4 A simple vasodilatory effect is probably compounded by the significant changes observed in the airways resistance and ventilation. Harris et all" suggested that the high alveolar and intrathoracic pressure compresses resistance vessels in the lung leading to an increase in pulmonary artery pressure. The increase in pulmonary vascular resistance, without any change in blood gas tensions which is observed after voluntary hyperventilation or exercise lends support to this view. Accordingly, the reduction of pulmonary vascular resistance after a drug such as terbutaline could be explained partially by its direct dilatory action on the bronchi.
It is difficult to assess the part played by the increased ventilation observed after the drug in reducing pulmonary arterial pressure. An apparent reduction as a result of an increase in the mid-thoracic diameter could reasonably be discounted because increased ventilation observed after exercise or voluntary hyperventilation at approximately similar flow as demonstrated after the drug leads to opposite changes in the pulmonary artery pressure. Hypoxia after underventilation in chronic bronchitis had been regarded traditionally as the major factor in the genesis of pulmonary hypertension.1 However, our group of patients had normal arterial blood oxygen saturation at rest as well as on exercise. The suggestion that increased ventilation after terbutaline may produce improvement in segmental hypoxia leading to reduction in pulmonary arterial pressure'5 cannot be discounted by the present study.
The changes in systemic circulation produced by terbutaline are compatible with beta-adrenergic receptor stimulation both centrally and in group.bmj.com on June 23, 2017 -Published by http://thorax.bmj.com/ Downloaded from the peripheral vasculature. Since the studies were performed in the supine position, one would expect less reflex response from the peripheral adrenergic activity. Significant increase in heart rate, cardiac/stroke output without any change in arterial pressure during exercise indicates enhancement of cardiac betareceptor activity. At rest however, the increase in heart rate and cardiac output probably was partially a reflex response to the reduction in mean systemic arterial pressure. Several investigators '6 have shown that the stimulation of beta-adrenergic activity produced by terbutaline, whether central or reflex in origin, is quantitatively less than that produced by other sympathomimetic amines when used in clinically effective doses. Despite this proviso, caution should be exercised in the use of these drugs in patients with associated ischaemic heart disease when an increase in cardiac work may upset the myocardial oxygen balance.
We used 250 '9 Attention has been drawn to the possible adverse effect of beta-adrenergic agonists on the ventilation/perfusion relationship in patients with chronic pulmonary disease.6 In our studies we failed to show any increase in venous admixture although a slight but significant fall in systemic arterial blood oxygen tension was observed at rest. The increase in alveolar ventilation coupled with improvement in the mixed venous oxygen saturation probably offset any imbalance in the ventilation/perfusion relationship.
